AHA: Novel Drug Effective for Hyponatremia in Heart Failure Patients - CME Teaching Brief® - MedPage Today: "CHICAGO, Nov. 15 -- Tolvaptan, an investigational selective oral vasopressin V2-receptor antagonist, restored serum sodium concentrations in heart failure and cirrhosis patients with hyponatremia, researchers reported here.
Compared with placebo patients in randomized, double blind studies of patients with euvolemic or hypervolemic hyponatremia, serum sodium concentrations increased in the tolvaptan arm by day four and the rise was durable at 30 days (P<0.001), said Mihai Gheorghiade, M.D., of Northwestern University. "
No comments:
Post a Comment